VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Feb. 13, 2007) - Pyng Medical Corp. (TSX VENTURE:PYT) is pleased to announce it has engaged StarFish Medical to design and develop the next generation of the FAST1(TM) Intraosseous Infusion System. FAST1(TM) is the only intraosseous infusion device able to provide rapid sternal access and delivery of life saving fluids and drugs to the heart of critically injured patients in seconds. "Pyng is committed to advancing and expanding our family of intraosseous infusion systems to address our expanding critical care markets in military, hospital, and emergency medical services," stated David Christie, President and CEO of Pyng.
StarFish Medical are specialists in contract medical device development and manufacturing. For over 10 years StarFish Medical has designed, developed and manufactured sophisticated medical devices for a select clientele. StarFish, based in Victoria, BC, was chosen for their ability to provide turnkey medical device design solutions under their ISO 13485 Quality System, and their experience with precision mechanical parts and plastic materials.
"We are excited by the opportunity to continue our partnership with Pyng in developing the next generation FAST1(TM). This technology will position Pyng as the dominant provider of intraosseous infusion products," said Scott Phillips, President of StarFish Medical.
About Pyng Medical Corp.
Pyng Medical Corp. is a world-leader in intraosseous infusion with its proprietary award-winning FAST1(TM) Intraosseous Infusion System. The FAST1(TM) is used extensively by the U.S. Department of Defense and by Emergency Medical Services around the globe.
Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.
FOR FURTHER INFORMATION PLEASE CONTACT:
Pyng Medical Corp.